US pay-for-delay deals up 60% in 2010
This article was originally published in SRA
Executive Summary
Deals in which innovator drug makers in the US paid generic manufacturers to keep cheaper versions of pharmaceuticals off the market shot up 60% in 2010, rising from 19 in 2009 to 31 last year1, according to the Federal Trade Commission.